P R E S S R E L E A S E

Lelystad, the Netherlands, 22 December 2009

FIRST INTERIM ANALYSIS THREE-YEAR ORALGEN® GRASS POLLEN STUDY FINALISED

- **Initial analysis finalised on schedule**
- **Results will remain blinded to protect the scientific integrity of the next stage**

Fornix BioSciences N.V. (Euronext Amsterdam: AFORBI) announces that the first interim analysis of the new multi-year clinical study AB0801 into the effectiveness and safety of Oralgen® Grass Pollen among adults with grass pollen-related allergic rhinoconjunctivitis (hay fever) that was commenced in early 2009 has now been finalised. The results have not, however, been made known to the company. This is connected to the decision to keep the results of the analysis blinded for the time being in the interest of the scientific integrity of the next stage of the study and the assessment of the data by the registration authorities. Fornix will publish the definitive results as soon as this process has been finalised.

AB0801 is a Phase III study that forms part of the clinical development plan of Oralgen® Grass Pollen within the framework of the Phase I study AB10601 and the Phase II/III studies AB0602 and AB0602/1 carried out previously.
The AB0801 study is a multi-centre, randomised, placebo-controlled, double-blind clinical study that evaluates the effectiveness and safety of a daily maintenance dosage of 19,000 BU of Oralgen® Grass Pollen versus placebo during three consecutive pollen seasons.

The study was commenced four months prior to the start of the 2009 pollen season. The study involves 373 adult patients with grass pollen-related allergic rhinoconjunctivitis from six European countries who were divided equally into the placebo group and the Oralgen® group. An interim analysis of the study results will be completed after the end of the 2009 and 2010 pollen seasons. The definitive analysis will take place after the end of the 2011 season.

The objective of treatment with Oralgen® Grass Pollen is to induce an immune response in allergic patients that is sufficient to treat both the allergic symptoms and the underlying cause of the allergic conditions and hence actually to cure the patient.

In view of the status of the evaluation, it remains unclear at this time to what extent the outcome of the first interim analysis of the new three-year Oralgen® Grass Pollen study will be able to contribute to obtaining registration for this product.

E N D O F P R E S S R E L E A S E

For further information, please contact:

Fornix BioSciences N.V.
C.L. Bergman
CEO
Tel. (0320) 26 77 99

www.fornix.nl

Profile of Fornix BioSciences N.V.

Fornix BioSciences N.V. is a listed company (Euronext Amsterdam, code AFORBI) which engages in the development and sale of diagnostic and therapeutic allergen products and the distribution of medical aids and medical and nursing consumables. Fornix BioSciences N.V. has sites in Lelystad, Beuningen and Hamburg. The company currently has a workforce of around 130 and is active mainly in the Netherlands and Germany.

Its activities are carried out by two divisions, which in turn are made up of operating companies. The Allergy Division, which consists of Artu Biologicals Europe and, since 1 June 2007, Artu Biologicals Deutschland, is the most profitable division. Its activities include the development, production and sale of a wide range of patient-friendly immunotherapeutic products, under the Oralgen®, Igevac® and other trade names. These products are used in the causal treatment of allergies triggered by various allergens, such as grass and tree pollen and house-dust mites. The development programme is supported by high-quality R&D activities and pan-European clinical studies of the effectiveness of the various products.

The Medical Aids Division, which consists of Laprolan in Beuningen, engages in the sale, marketing and distribution of a wide range of medical aids and medical and nursing consumables.